Cardiac stereotactic body radiotherapy to treat malignant ventricular arrhythmias directly affects the cardiomyocyte electrophysiology
Christine Mages(MetLife (United States)), Patrick Lugenbiel(Heidelberg University), Ann‐Kathrin Rahm(Heidelberg University), Heike Gampp(Heidelberg University), Antoine A.F. de Vries(Leiden University Medical Center), Fatemeh Kermani, Katharina Seidensaal(Heidelberg University), Dierk Thomas(Heidelberg University), Daniël A. Pijnappels(Leiden University Medical Center), Nina D. Ullrich(University of Bern), Bernhard Rhein(Heidelberg University), Juline Hackbarth(Heidelberg University), Finn Petersenn(Heidelberg University), Xenia C. Kramp(Heidelberg University), j. william pfeiffer(Heidelberg University), Juan Zhang(Leiden University Medical Center), Jürgen Debus(Heidelberg University), Norbert Frey(University Hospital Schleswig-Holstein)
Cited by 15
Related Papers
Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial
|The Lancet|2020|1.2k
Left Ventricular Unloading Is Associated With Lower Mortality in Patients With Cardiogenic Shock Treated With Venoarterial Extracorporeal Membrane Oxygenation
|Circulation|2020|502
RIP3, a kinase promoting necroptotic cell death, mediates adverse remodelling after myocardial infarction
|Cardiovascular Research|2014|316